News and Trends 9 Sep 2022 Improved vision with less eye injections for patients after primary endpoints met in trials The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […] September 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Clearance given to clinical trial with potential to change course of brain disease A trial to look at gene therapy, BV-01, for Huntington’s Disease has been given the go ahead to take place in France and has ‘the potential to change the course of the devastating disease. Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, received clearance for the phase 1/2 […] August 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M U.S. cell programming company Ginkgo Bioworks has signed definitive agreements to acquire two teams and technologies. The deals are with Bayer and Zymergen. Bayer transaction The company confirmed the previously announced transaction with Bayer to expand Ginkgo’s platform capabilities in agricultural biologicals. Ginkgo will acquire Bayer’s 175,000-square-foot West Sacramento Biologics Research & Development site, team, […] July 26, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jun 2022 Expansion into Europe for BlueRock Therapeutics BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. The move comes as part of the company’s growth strategy. A multidisciplinary BlueRock team will be set up during 2022 to provide clinical development and operational […] June 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Nov 2021 Big Pharma Strikes Megadeals In Targeted Protein Degradation With many targeted protein degraders hitting the clinic, lucrative collaborations and acquisitions are being signed between biotech startups and big pharma in this upcoming area. Novartis, Pfizer, and Bayer have all negotiated billion Euro deals this year with smaller biotechs including Dunad Therapeutics, Arvinas, and Vividion Therapeutics. The big pharma companies aim to gain a […] November 12, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2021 Farxiga’s Approval Fuels Chronic Kidney Disease Comeback Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […] June 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Aug 2020 Women’s Health Gains Traction as Bayer Pays €736M for UK Firm Bayer’s recent €736M ($875M) acquisition of KaNDy Therapeutics could herald growing investor interest in women’s health – a historically neglected field in the biotech and pharma industry. Through this deal, Bayer has snapped up KaNDy Therapeutics’ first-in-class drug for treating hot flashes and night sweats, which often occur during the menopause. In a phase IIb […] August 18, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2020 Meiogenix, Bayer Team Up to Boost Genetic Diversity in Crop Breeding Bayer and the French biotech company Meiogenix will work together to advance the development of Meiogenix’s plant breeding and genome editing technologies with the hope of improving food crops for farmers. For many years, the only way to improve characteristics such as yield and nutritional value of crops was through selective breeding, which can be […] February 10, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 11 Jul 2019 Bayer Launches Israeli Company to Develop Viruses Against Crop Disease Bayer is backing the launch of the Israeli biotech Ecophage, which will develop environmentally friendly crop disease treatments based on bacteria-hunting viruses called bacteriophages. Bacteria can cause a range of diseases in crops, including blight and root rot. These infections are often hard to control because they happen faster than fungal infections. The treatments used […] July 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 28 Jun 2018 The Race to Get CRISPR to the Clinic: Hope Versus Hype In 2016, German pharma giant Bayer took a bold step and decided to partner with CRISPR Therapeutics to form a company that could join the race to be first into the clinic with a CRISPR therapy. Peter Nell worked at Bayer for many years and was one of the founding team of Casebia Therapeutics. Now […] June 28, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 20 Jun 2018 “Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech Some careers take on an international scope and span the breadth of big players in the pharmaceutical industry and small biotech startups. David Ebsworth, Chairman at Verona Pharma, can count his professional journey among these and gave us the inside scoop on the successes and challenges he faced, his perspective on European biotech, and advice to […] June 20, 2018 - 9 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 17 May 2018 After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology. The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses […] May 17, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email